INDIVIOR PLC/S (INVVY) Raised to “Hold” at Zacks Investment Research
INDIVIOR PLC/S (OTCMKTS:INVVY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
Other research analysts have also issued reports about the company. ValuEngine lowered INDIVIOR PLC/S from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 29th. Jefferies Financial Group cut INDIVIOR PLC/S from a “buy” rating to a “hold” rating in a research note on Wednesday, November 21st.
INDIVIOR PLC/S (OTCMKTS:INVVY) last announced its earnings results on Thursday, November 1st. The company reported $0.40 EPS for the quarter. The firm had revenue of $245.00 million for the quarter. As a group, research analysts expect that INDIVIOR PLC/S will post 1.8 EPS for the current fiscal year.
INDIVIOR PLC/S Company Profile
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Further Reading: Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.